Costs of treatment

Following last month’s report on the implications of development of Eli Lilly’s chemotherapy drug, Alimta, separate research from Newcastle University, to be published late in August in the Journal of Clinical Oncology , on the life-extension of victims of mesothelioma receiving combined treatment with pemetrexed and carboplatin, raise the same issues of cost and compensation.